KKR acquires Karo Healthcare
KKR, a leading global investment firm, has entered into an agreement to purchase all shares in Karo Healthcare from EQT.
Karo Healthcare is a leading European consumer healthcare company with the purpose of delivering “Smart choices for everyday healthcare”. Karo Healthcare is headquartered in Stockholm, and employs about 470 people working out of the group’s 13 international hubs. In 2024, Karo Healthcare achieved revenue of EUR 530 million and its products (including brands such as Lamisil, E45, Pevaryl, Proct, AlphaFoods, Nutravita, Flux, Locobase, Multi-Gyn and Paracet) reached consumers in more than 90 countries.
Completion of the transaction is subject to customary conditions and regulatory approvals. The transaction is expected to close in the coming months.
Mannheimer Swartling advised KKR in the transaction.
